



COMPOSE Study

A study that looks at the safety of pegtibatinase and how well it may work in people with classical homocystinuria (HCU)



NOW ENROLLING

Traverse Therapeutics has added a pediatric group to study pegibatinase, a new, investigational human enzyme therapy that targets the underlying enzyme deficiency that causes HCU.

The goal of this study is to learn more about the safety and efficacy of pegitbatinase at different dosage levels in children with HCU.

Up to 15 participants will take part in the study at sites in the United States, France, and Qatar. The study, including a screening period, diet standardization period, and an open-label treatment period, will last up to 42 weeks (~10 months). There is also an option to join a long-term extension study (ENSEMBLE).

Your child may be eligible to participate in the COMPOSE Study if they:

- Have been diagnosed with classical HCU
- Are 5 to 11 years of age
- Are currently receiving treatment for HCU

Your child will need to meet all other study criteria to take part in the COMPOSE Study.



For additional information on criteria for eligibility, please go to:
www.clinicaltrials.gov/show/NCT03406611

Payment for time and travel may be available to subjects who participate in this study.
To refer a patient to the study, **please contact:**

MedInfo@traverse.com

Visit www.hcuconnection.com for more information.

